Curevac N.v Stock News

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the p

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the p

CVAC earnings call for the period ending March 31, 2022.

CureVac NV (NASDAQ:CVAC ) Q4 2021 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Moderna Inc (NASDAQ: MRNA) submitt

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucl

Shares of CureVac CVAC, -0.28% were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline GSK, +0.89% said they signed an agreement with the German government for pandemic prepa

The World Health Organization said Wednesday it's increasingly concerned at the reduction in COVID-19 testing, surveillance and overall monitoring among its member countries, reminding the public that

Shares of CureVac CVAC, +0.47% were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's d

They're winning when it comes to orders.

During the last session, CureVac N.V. (NASDAQ:CVAC)’s traded shares were 0.31 million. At the end of the trading day, the stock’s price was $15.69, reflecting an intraday loss of -6.44% or -$1.08. The 52-week high for the CVAC share is $130.48, that puts it down -731.61 from that peak though still a striking 9.5% gain … CureVac N.V. (NASDAQ: CVAC): Can A Stock That’s Down -54.27% YTD Still Be Considered In Loss Territory? Read More »

GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

CureVac (CVAC) formed a new subsidiary called CureVac RNA Printer GmbH to advance its RNA Printer((R)) technology which integrates and automates manufacturing for RNA vaccines…

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.